Navigation Links
Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
Date:10/4/2010

FLORHAM PARK, N.J., Oct. 4 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the non-stimulant medication KAPVAY™ (clonidine hydrochloride) extended-release tablets, an extended-release oral formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6-17 years. KAPVAY™ is the only formulation of clonidine hydrochloride approved by the FDA for the treatment of ADHD, and is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication. KAPVAY™ can also be used as monotherapy when treating ADHD.

An oral, non-stimulant, twice-daily therapy, KAPVAY™ is a centrally acting alpha2-adrenergic receptor agonist. While the mechanism of action of alpha2 agonists in ADHD is not known, it is believed to involve the pre-frontal cortex (PFC) of the brain. Studies suggest that the PFC regulates attention and plays a critical role in impulse control, working memory and executive function.

"The FDA approval of KAPVAY™ represents an exciting milestone in the field of ADHD," said Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc. "The extended-release formulation of KAPVAY™ minimizes the peaks and troughs in blood levels, thereby decreasing overactivation of the alpha receptors in the brain and periphery. We look forward to providing this important, beneficial treatment for ADHD to patients, both as monotherapy and add-on therapy to stimulants."

"ADHD is a complex disorder that requires individualized treatment. While there are prescription treatment options available, many ADHD patients on stimulants do not achieve adequate control of symptoms," explained Rakesh Jain, MD, MPH, Director of Psychiatric Drug Research for R/D Clinical Research at Lake Jackson, Texas, and an investigator in the clinical trials. "KAP
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan
2. BioCrysts Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
3. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
4. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
5. Bioheart, Inc. Announces Loan to be Assumed by Seaside
6. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
7. IGEN AMENDS DISTRIBUTION AGREEMENT AND ANNOUNCES FIRST SPECTRUM BUILD-OUT
8. Crescendo Biologics Announces First Triple Knockout Mouse
9. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
10. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
11. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... York , September 23, 2014 ... leading provider of  Closed System Transfer     Devices ... exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s ... in Taiwan , ... as the company continues to expand globally, and ...
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... Scheduled for Thursday, May 15th at 5 PM ... ... IMRX ) today announced that the Company has postponed its live,webcast and ... quarter 2008 financial results; this call was originally,scheduled for Tuesday, May 13, 2008, ...
... Interleukin Genetics,Inc. (Amex: ILI ) announced today that ... Rodman and Renshaw 5th Annual Global,Healthcare Conference on Monday ... The conference will be held at Le Meridien Beach ... of the presentation will be available on the,Investors section ...
... BETHLEHEM, Pa., May 13 Particle Sciences has expanded,its ... ft Class 1000 (ISO 6),clean room. The space also ... was added to the existing 15,000 sq ft facility ... manufacturing,especially that of semisolids, suspensions and dispersions. "This,investment is ...
Cached Biology Technology:Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/23/2014)... 2014 Research and Markets  has announced ... and Opportunities, 2019" report to their offering. ... enhancing security and protection in private as well as ... country,s government is focusing on using biometric systems to ... national IDs that are of crucial importance to the ...
(Date:9/23/2014)... CORAL SPRINGS, Florida , September 23, 2014 ... listings for innovative companies in tech sector position for significant ... generation products & services.  Companies in focus today are: NXT-ID, ... (NYSE: BABA ), Mobileye N.V. (NYSE: ... ReWalk Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/23/2014)... have parasitic DNA fragments called "jumping genes" that insert ... process. And that phenomenon can result in age-related diseases ... Rochester now report that the "jumping genes" in mice ... protein stops keeping them in check in order to ... published today in Nature Communications , Professor of ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... the 20th EORTCNCIAACR Symposium on "Molecular Targets and ... from Tuesday 21 October-Friday 24 October. Today ... accommodation via the official local agent if you ... the European Organisation for the Research and Treatment ...
... national trial of a catheter-based treatment for deep ... in combination with clot removal devices to prevent ... of a blood clot in a leg vein). ... permanent damage to the veins, resulting in debilitating ...
... Wayne State University have tested a breast cancer vaccine ... even cancers resistant to current anti-HER2 therapy - without ... 15 issue of Cancer Research, a journal ... vaccine could treat women with HER2-positive, treatment-resistant cancer or ...
Cached Biology News:Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3Vaccine against HER2-positive breast cancer offers complete protection in lab 2Vaccine against HER2-positive breast cancer offers complete protection in lab 3
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: